Table 3.
Performance of the biomarkers for the diagnosis of cholangiocarcinoma.
| Tumor Markers (cut-off value) | Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | LR+ (%) (95% CI) | LR- (%) (95% CI) |
|---|---|---|---|---|
| NGAL | 100 | 26 | 1.35 | — |
| (50 ng/mL) | (-) | (14–38) | (1.35–1.59) | (-) |
| NGAL | 76 | 72 | 2.71 | 0.33 |
| (110 ng/mL) | (64–88) | (60–84) | (1.69–4.35) | (0.20–0.56) |
| CA19-9 | 76 | 74 | 2.96 | 0.32 |
| (35 U/mL) | (64–88) | (62–86) | (1.79–4.79) | (0.19–0.55) |
| CA19-9 | 72 | 86 | 5.14 | 0.33 |
| (100 U/mL) | (60–84) | (76–96) | (2.53–10.44) | (0.21–0.51) |
| Combined markers* | 90 | 66 | 2.65 | 0.15 |
| (82–98) | (53–79) | (1.78–3.94) | (0.06–0.36) |
LR+; positive likelihood ratio, LR‒; negative likelihood ratio, CI; confidence interval. *; Combination of NGAL (cut-off value = 110 ng/mL) and CA19-9 (cut-off value = 100 U/mL).